Daniel Spratt, MD, discusses key updates to the National Comprehensive Cancer Network Guidelines for prostate cancer.
Outlining the Evolving Efficacy and QOL Outcomes Associated With ADT in Prostate Cancer
Outlining the Evolving Efficacy and QOL Outcomes Associated With ADT in Prostate Cancer
Dr Shore discusses the use of ADT in patients with prostate cancer, as well as toxicities and quality-of-life complications associated with these agents.
Dr Dorff discusses the role of ADT in prostate cancer management, how this class has evolved, and the use of relugolix across treatment settings.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma
2
Dr Reiss Binder on the FDA Approval of Daraxonrasib for Metastatic PDAC
3
ASCO Issues Warning Regarding Ifosfamide Shortage for Cancer Care
4
Dr Ayanambakkam on the Safety of Darlifarnib Plus Cabozantinib in RCC KD
5